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cerous latent period. Diagnostic
strategies are available to identify
those with the risk factors and treat
them in the precursor stage; and to
identify and treat endoscopically or
surgically those in the early submu-
cosal stage of the cancer when five-
year survival rates are favourable.
The incidence and mortality of
gastric cancer has fallen substan-
tially in many Western countries in
the past three decades, with a decre-
ase in well-differentiated distal non-
cardia cancer but an increase in pro-
ximal diffuse adenocarcinoma of the
cardia. Distal gastric cancer is rela-
ted to gastric atrophy and intestinal
metaplasia and predominates in de-
veloping countries and individuals
with lower socio-economic status wi-
thin Western societies. The proximal
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G astric cancer is the se-cond cause of cancerdeaths worldwide formales and fourth for
females according to Correa1 and to
Watabe2 and Portugal is third out of
28 European countries in rates of
gastric cancer. In 2000 an estimated
876,000 individuals were diagnosed
and 649,000 died from stomach
cancer worldwide each year.3 In 
most countries it is diagnosed after
it has invaded the muscularis pro-
pria and the five-year survival is less
than 20%.4 Conventional therapy
has had minimal impact on survival.
The pathological precursor stage of
the disease provides a long precan-
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cardia tumours are related to pan-
gastritis without atrophy and are
more common in developed coun-
tries and individuals with higher so-
cio-economic status. The main risk
factor for the distal non-cardia type
is H. pylori infection, whereas gastro-
esophageal reflux and obesity play
important roles in the development
of cancers of the cardia. There is a
ten-fold variation in gastric cancer
rates worldwide, with Japan and Ko-
rea having the highest rates.5
Gastric cancer has a multifacto-
rial etiology: long-term colonisation
with H. pylori; a diet high in salt and
N-nitroso compounds and low in
fruit and vegetables; a dose-depen-
dent relationship to tobacco smo-
king (OR = 2.0); and obesity for gas-
tric cardia adenocarcinoma.5
H. pylori is present in the sto-
machs of 50% of the world’s popu-
lation;6 30% in the developed world,
60 % in the developing world, and in
85% of the Portuguese population.
It is usually acquired in childhood
(Level B Evidence: prospective co-
hort study): 7 in a study in Sapporo,
Japan, of 345 pregnant females
found 20% had positive serology for
H. pylori and the researchers fol-
lowed 51 of their children, of whom
11% acquired H. pylori, with DNA
strains identical to those of their mo-
ther. It may also be transmitted bet-
ween children by episodes of gastro-
enteritis, and colonisation is related
to low socioeconomic status, over-
crowding, and country of origin (Le-
vel C Evidence: expert review).8
The aim of this review is to assess
whether there is a relationship bet-
ween Helicobacter pylori infection
and gastric cancer.
Searches: We searched the Cochra-
We included RCTs, cohort, and
case-control studies, interrupted
time series, systematic reviews and
meta-analyses, and excluded non-
systematic reviews.
Evaluation of the Level of Eviden-
ce: We used the rating system of the
American Family Physician: Level A
(randomised controlled trial/meta-
analysis; Level B (other evidence);
and C (consensus/expert opinion).9
The search terms Helicobacter pylo-
ri AND cancer AND meta-analysis
OR systematic review identified 3
studies in DARE, 3 in the Cochrane
Database of Systematic Reviews, 63
in EMBASE, 45 in MEDLINE and 21
in Biological Abstract/BIOSIS Pre-
views. Of these, 31 studies provided
data on the relationship between He-
licobacter pylori and stomach cancer,
and 54 were excluded, as on closer
inspection they did not provide data.
It is difficult to estimate bias in the
included compared to the excluded
studies as most did not cite whether
they received funds from a pharma-
ceutical company or not.
H. pylori increases the odds ratio of
gastric cancer in various studies by
2.1 to 16.7. The longer the individual
has H. pylori the higher the risk of
developing gastric cancer.8
H. pylori is associated with the de-
velopment of both types of gastric
adenocarcinoma (intestinal type and
diffuse type).8 The stages of develop-
ment of intestinal type gastric ade-
nocarcinoma are better understood,
and consist of the transition from
ne Central Register of Controlled 
Trials (CENTRAL), the Cochrane Da-
tabase of Systematic Reviews, and
the NHS Database of Abstracts of
Reviews of Effectiveness (DARE) (all
to Cochrane Library Issue 1, 2006);
MEDLINE (OVID, January 1966 to
April 2006 week 1); EMBASE (Dia-
log 1974 to 1979; SilverPlatter 1980
to April 2006 week 1), Biological Abs-
tracts (SilverPlatter 1969 to April
2006) and Science Citation Index-
-Expanded (Web of Science 1974 to
April 2006). We used the search
terms Helicobacter pylori and (gas-
tric or stomach) and (cancer$ or neo-
plasm$) and (systematic review$ or
meta-anal$), and searched for arti-
cles in all languages and limited the
search to humans. The Science Ci-
tation Index-Expanded was used to
identify articles that cite the relevant
studies. The relevant studies were
also keyed into PubMed and the Re-
lated Articles feature used. We selec-
ted for review all those articles which
from their abstract or title appeared
to be relevant, and obtained full-text
versions if the abstract or title to as-
sess them fully. We then reviewed all
the relevant articles in full text.
MeSH terms (non-mesh indica-
ted by .mp) used in three separate
searches:
- Helicobacter pylori AND dyspepsia
OR dysphagia.mp OR duodenal
ulcer OR stomach ulcer OR gas-
tritis OR deglutition disorders
- Helicobacter pylori AND antibo-
dies OR Enzyme-Linked Immu-
nosorbent Assay OR elisa.mp OR
breath tests OR serology OR se-
rum OR feces OR stool.mp OR sa-
liva OR pepsinogen A or pepsino-
gen.mp OR endoscopy
- Heliocobacter pylori AND cost-be-
nefit analysis OR cost-effecti-
ve.mp OR sensitivity and specifi-
city OR predictive value of tests
OR mass screening.
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normal mucosa through chronic su-
perficial gastritis, atrophic gastritis,
intestinal metaplasia and dysplasia
to adenocarcinoma.8 The WHO10 has
classified H. pylori as a class I carci-
nogen for gastric cancer.
Danesh reviewed 34 retrospecti-
ve sero-epidemiological studies of
the association of H. pylori and gas-
tric cancer and retained 25 for ana-
lysis but concluded that the controls
were of uncertain validity (Level A
Evidence: systematic review).11 The
ten case-control studies nested wi-
thin prospective studies had about
800 participants and the risk ratio
of H. pylori sero-positivity for gastric
cancer was 2.5 (95% CI = 1.9 to 3.4);
all the ten studies adjusted for age
and gender but only some adjusted
for smoking history, diet or social
class.
Uemura followed 1,526 patients
with duodenal or gastric ulcers, gas-
tric hyperplastic polyps or non-ulcer
dyspepsia for an average of 7.8
years; 1,246 were H. pylori positive
(Level B Evidence: prospective co-
hort study). 12 In the infected group
36 (2.9%) developed gastric cancer
(23 intestinal-type and 13 diffuse-
type) and none in the 253 in the H.
pylori group treated with antibiotics
and followed up for an average of
4.8 years, or in the non-infected
group. The average age of diagnosis
was 53 years in the gastric ulcer and
63 in the non-ulcer dyspepsia group.
Watabe2 performed the first large
population-based study and fol-
lowed 6,983 of the 9,293 partici-
pants in a health appraisal program-
me for 4.7 years with an average of
5.1 endoscopic examinations, and
43 developed gastric cancers during
this period. He found that the group
of 443 with “atrophic” levels of pep-
sinogen and who were negative for
H. pylori antibodies had an annual
incidence of gastric cancer of 0.6%;
the group of 3,324 with normal pep-
sinogen levels and who were negati-
ve for H. pylori antibodies had an
annual incidence of 0.04%; the
group of 2,134 with normal pepsi-
nogen and who were positive for H.
pylori antibodies a rate of 0.06%;
and the group of 1,082 with “atrop-
hic” levels of pepsinogen and who
were positive for H. pylori antibodies
a rate of 0.36%.
H. pylori is also related to gastric
carcinoma in animals. One third of
Mongolian gerbils infected with H.
pylori developed gastric carcinoma
over a two-year period (Level C Evi-
dence: expert review).13-14
However, on average only three
per cent of those who carry H. pylo-
ri develop gastric carcinoma.8 For
specific individuals who carry H.
pylori the risk of gastric carcinoma
is increased by at least four factors
(the genetic sequences of the H. pylo-
ri strains; patient polymorphisms
that express higher levels of the
cytokine IL-1β; the expression of hig-
her levels of (TNF)-α; and if the indi-
vidual has major histocompatibility
complex genotypes that are upregu-
lated by H. pylori and affect how the
epithelium responds to the inflam-
mation caused by H. pylori).
The individual may carry strains
of H. pylori, which, due to mutations,
substitutions, deletions and inser-
tions have gene sequences that are
more carcinogenic and these can
also be transmitted between strains.
The gene sequences cag (which al-
lows bacterial proteins to enter host
epithelial cells), vacA, and babA2
(which permits adhesion of bacteria
to the cell surface) are associated
with an increased risk of gastric can-
cer (Level B evidence: genome se-
quence studies),8,15,16 and strains that
possess all three genes have the hig-
hest risk.8
The risk of gastric cancer is also
increased if the individual has poly-
morphisms that result in the expres-
sion of higher than average levels of
the cytokine IL-1β (Level B Eviden-
ce: study of interleukin polymor-
phisms).17 IL-1β is the most power-
ful suppressor of gastric acid secre-
tion and causes marked inflamma-
tion. Administration of recombinant
IL-1β receptor antagonists to Mon-
golian gerbils normalises their gas-
tric acid levels (Level B Evidence: co-
hort study).18 Specifically, carriers of
the IL-1 1B-511T and IL-1RN*2 ho-
mozygotes have an increased risk of
developing gastric cancer (Level B
Evidence: study of interleukin re-
ceptors).19
The risk is also increased if H.
pylori proteins increase levels of the
(TNF)-α factor, which suppresses
gastric acid production and increa-
ses gastric inflammation (Level B
Evidence: interleukin studies).20-22
Other pathways by which H. pylo-
ri induces cancers at the cellular le-
vel include the release of nitric oxi-
de synthase, nitric oxide, and supe-
roxide anion radicals; apopotosis;
and the conversion of N-nitrosami-
nes to nitrites.8
A systematic review identified
eight case-control studies and one
cohort study of the relationship
between aspirin and gastric cancer
and three reviewers independently
assessed study quality. The meta-
-analysis concluded that NSAID use
is associated with a significant re-
duction in the risk of non-cardia gas-
tric cancer (OR = 0.72; 95%CI = 0.58
to 0.89) but not of cancer at the car-
dia (OR = 0.80; 95% CI = 0.53 to
1.20). The prospective cohort study
followed 635,031 individuals for six
years and found that the relative risk
of gastric cancer for aspirin users
was RR = 0.64 (95%CI = 0.51 to 0.80)
compared to the non-users. The
hypothesized relationship between
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endoscopy was performed. The
correlations between the patholo-
gists on the weighted index of seven
biopsy scores were ρ = 0.71 at base-
line, ρ = 0.81 at 6 weeks, ρ = .088 at
one year and the correlation betwe-
en the changes seen at six weeks
and one year was r = 0.44. The ana-
lysis was by intention-to-treat. The
cure rate for H. pylori in the experi-
mental group at one year was 76%,
and the weighted index of biopsies
improved compared to placebo 
(p = .03). Problems in this study were
the less than optimal agreement
between the pathologists and the
cure rate of 76%.
Wong randomised 1,630 patients
in Fujian Province, China, with H.
pylori to receive either two weeks of
omeprazole, amoxicillin and clavu-
lanate, and metronidazole, or place-
bo and followed them for an avera-
ge of 7.5 years (Level A Evidence:
randomised controlled trial).27
Eighteen patients developed gastric
cancer, with no differences between
the H. pylori treated and untreated
groups, but in the group with no
pre-cancerous lesions at baseline no
patient developed gastric cancer
compared with six in the placebo
group (p = .02).
Correa showed that patients in
Columbia who received treatment
for H. pylori had an odds ratio of re-
gression of gastric metaplasia of 3.1
(95% CI = 1.0 to 9.3) and regression
of gastric atrophy of 8.7 (95% CI =
2.7 to 28.2) (Level A Evidence: ran-
domised controlled trial).28
Leung randomised 587 patients
in Shandong province, China, with
H. pylori to receive either a week of
omeprazole, amoxicillin and cla-
rithromycin or placebo and followed
them for five years (Level A Eviden-
ce: randomised controlled trial);29
75% of those treated were clear of H.
pylori at five years. Persistent H.
pylori infection (OR = 2.13; 95% 
CI = 1.41 to 3.24; age > 45 years 
(OR = 1.92; 95% CI = 1.18 to 3.11);
alcohol use (OR = 1.67; 95% CI =
1.07 to 2.62); and drinking water
from a well (OR = 1.74; 95% CI =
1.13 to 2.67) were independent risk
factors for progression of intestinal
metaplasia. Ten patients (2.3%) de-
veloped gastric cancer, with six in
the control and four in the experi-
mental group, but as all ten died it
is likely they were all in advanced
stages. The highest risk of progres-
sion to gastric cancer was in those
> 45 years with persistent H. pylori,
and duodenal ulcer patients had a
low risk of progression of intestinal
metaplasia (OR = 0.23; 95% CI =
0.09 to 0.58).
Uemura found that patients with
early gastric cancer who received
therapy to eradicate H. pylori had
significantly reduced rates of atrop-
hic gastritis and recurrence of gas-
tric cancer (Level B Evidence: pros-
pective cohort study).30
In a study of 115 patients with
gastric MALT lymphomas, 86% were
positive for H. pylori and of these
73% showed tumour regression af-
ter antibiotic therapy (Level B Evi-
dence: prospective cohort study).31
Gastric cancer is preceded by a long
latency period before it invades the
muscularis propria. Infection with
H. pylori is a primary cause of the
precancerous cascade from gastritis
to dysplasia, and eradicating H. pylo-
ri by antibiotic therapy results in a
modest retardation of the cancerous
process.4
Most trials have been in adults in
a rather advanced stage of gastric at-
rophy and intestinal metaplasia, in
whom H. pylori had been present for
NSAID use and gastric cancer is that
the cycloxygenase 2 gene Cox-2 is
overexpressed in gastric cancers,
and that NSAIDs inhibit the produc-
tion of both Cox-1 and Cox-2 (Level
A Evidence: systematic review).23
There is no evidence that nutritio-
nal supplements prevent gastric
cancer. Malila gave alpha-tocophe-
rol or beta-carotene to middle aged
smokers in Finland and found no ef-
fect on gastric cancer rates (Level A
Evidence: randomised controlled 
trial).24 Bjelakovic in a Cochrane
systematic review found no benefit
of beta-carotene, vitamins A, C or E,
or selenium (Level A Evidence: syste-
matic review).25
Ley in Chiapas, Mexico, an area with
both high H. pylori and gastric can-
cer rates, enrolled 1,344 healthy vo-
lunteers to participate in a trial of
treating H. pylori (Level A Evidence:
randomised controlled trial);26 1,178
(87%) gave a blood sample; 468
(40%) were found to be both cag
positive and have gastrin levels
≥25µg/ml; and 316 (67% of 468)
were randomised to receive either
omeprazole, amoxicillin and cla-
rithromycin or placebo. The po-
wer computation assumed a back-
ground 10% regression rate of in-
flammation, and found that 240 pa-
tients would be needed to identify a
3-fold difference in response rates
between the study arms with 97%
power and significance level of 5%,
assuming 10% dropouts. Ninety-
three per cent of the patients in the
experimental arm took more than
90% of their prescribed pills. The
biopsies were read independently by
two pathologists blinded to the treat-
ment arm and the time when the
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several decades. The research to
date reviewed above suggests that
the best strategy is twofold. Firstly,
focus on high risk individuals with
known risk factors of H. pylori expo-
sure, “atrophic” pepsinogen levels,
and known pre-cancerous gastric
histopathology, treat them for H.
pylori and screen them endoscopi-
cally for the development of early
gastric cancers which can be ideally
resected endoscsopically. Secondly,
screen younger individuals (< 45
years) at risk for H. pylori who have
not been exposed to H. pylori for as
long and treat them.32
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RESUMO
O objectivo da presente revisão é avaliar se existe uma relação entre a infecção por Helicobacter
pylori e cancro gástrico.
Pesquisámos o Cochrane Central Register of Controlled Trials, o Cochrane Database of Systematic
Reviews e o NHS Database of Abstracts of Reviews of Effectiveness; MEDLINE; EMBASE; Silver-
Platter, Biological Abstracts and Science Citation Index-Expanded. Usámos os termos de pesquisa
Helicobacter pylori e (gastric or stomach) and (cancer$ or neoplasm$) e (systematic review$ or
meta-anal$), e pesquisámos artigos de todas as línguas limitando a pesquisa a humanos.
Avaliação do Nível de Evidência: usámos o sistema de classificação da revista American Family Physi-
cian: Nível A (ensaios clínicos aleatorizados/meta-análises). Nível B (outras fontes de evidência).
Nível C (consensos/opinião de peritos).
O H. Pylori aumenta a OR para cancro de estômago em vários estudos. O H. Pylori está associado
ao desenvolvimento de ambos os tipos de adenocarcinoma gástrico. Em média, apenas três por cen-
to dos portadores de H. Pylori desenvolvem carcinoma gástrico. O risco de cancro de estômago está
igualmente aumentado se o indivíduo tem polimorfismos que resultam numa expressão maior do
que os níveis médios da citocina IL-1β. Não existe evidência que os suplementos nutricionais previ-
nam o cancro gástrico.
O cancro gástrico é precedido por um longo período de latência. A infecção por H. pylori é uma causa
primária da cascata pré-cancerosa da gastrite à displasia e a erradicação do H. pylori por terapêuti-
ca antibiótica resulta num atraso moderado do processo canceroso. A investigação apresentada re-
vista até hoje sugere que a melhor estratégia é, primeiro, incidir nos indivíduos de alto risco com
factores de risco conhecidos de exposição ao H. pylori e rastreá-los endoscopicamente para o desen-
volvimento de cancros gástricos iniciais que podem ser ressecados endoscopicamente; seguidamen-
te, rastrear indivíduos mais novos (< 45 anos) em risco para H. pylori que não foram expostos ao
H. pylori por um período tão longo e tratá-los.
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